Delivery Order SPE2DB25D3012-SPE2DB25FXAEU
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 18, 2025, for the supply of Tagrisso 80 mg tablets (30-count units) valued at $10,662.57. This firm fixed price delivery order, with an ultimate completion date of September 9, 2025, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical. The award was competitively procured with no set-aside designation. AmerisourceBergen,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on June 9, 2025, for the supply of Tagrisso 80 mg tablets (30-count packages) valued at $10,662.57 under a Firm Fixed Price contract type. This delivery order represents a child contract issued against AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a comprehensive global pharmaceutical support vehicle valued at $999,999,999.00 and extending through December 2026....
- The Defense Logistics Agency awarded a delivery order valued at approximately $32,000 to AmerisourceBergen Drug Corp for the supply of Tagrisso 80 mg tablets (30-count units) on July 25, 2025, with an ultimate completion date of August 15, 2025. The contract utilizes firm fixed pricing with no set-aside designation, indicating competitive award. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor and critical federal vendor specializing in...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of Tagrisso 80 mg tablets (30-count units) under a firm fixed-price contract with a ceiling value of $10,662.57. The contract, which carries no set-aside designation, is a competitively awarded delivery order with an ultimate completion date of August 18, 2025. This award represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 8, 2025, for the supply of Tagrisso 80 mg tablets (30-count units) valued at $10,662.57 under a firm fixed price contract. This delivery order, which is a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (designated SPE2DX and valued at $999,999,999.00 through December 2026), represents a competitive, non-set-aside award with an ultimate...
- The Defense Logistics Agency (DLA) awarded AmerisourceBergen Drug Corp a delivery order valued at $10,662.57 on September 16, 2025, for the supply of Tagrisso 80 mg tablets (30-count units). This competitively awarded, firm fixed-price delivery order is scheduled for completion by October 7, 2025, with performance taking place at AmerisourceBergen's facility in Conshohocken, Pennsylvania. The contract carries no set-aside designation, reflecting open competition among qualified vendors. This...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on June 9, 2025, for the supply of Tagrisso 80 mg tablets (30-count units) under a firm fixed-price contract with a ceiling value of $42,650.28 and an ultimate completion date of July 1, 2025. This competitive award, which involved no set-aside designation, leverages AmerisourceBergen's position as a critical pharmaceutical distributor for federal medical procurement. The delivery order is a child contract...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, PA, was awarded a delivery order valued at $10,662.57 by the Defense Logistics Agency (DLA) on April 21, 2025, for the supply of Tagrisso 80 mg tablets (30-count units). This firm fixed-price, non-competitive delivery order is scheduled for completion by May 12, 2025, and represents a continuation of the company's extensive pharmaceutical supply relationship with the federal government. The award was...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $10,641.07 to AmerisourceBergen Drug Corp for the supply of Tagrisso 40 mg tablets (30-count). This is a firm fixed-price, non-set-aside contract with an ultimate completion date of September 24, 2025. The award was made on September 3, 2025, with the place of performance in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. This delivery order is issued under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a delivery order valued at $31,987.71 to AmerisourceBergen Drug Corp for the supply of Tagrisso 80 mg tablets (30-count units) on August 27, 2025, with an ultimate completion date of September 18, 2025. This competitive award, with no set-aside designation, reflects firm fixed-price pricing terms and represents a pharmaceutical supply delivery to support federal medical procurement needs. The place of performance is AmerisourceBergen's corporate office...
- SPE2DB25D3012Indefinite Delivery Contract
- SPE2DB25D3012-SPE2DB25FXAEUDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 17, 2025, for the supply of Tagrisso 80 mg tablets (30-count packaging) with a ceiling value of $213,036.40. This firm fixed price delivery order, with an ultimate completion date of October 8, 2025, represents a competitively awarded, non-set-aside transaction supporting federal medical procurement needs. The award is a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999 and extending through December 2026, which serves as a comprehensive global pharmaceutical support vehicle for military healthcare programs worldwide. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving as a critical vendor for federal medical supply chains, particularly supporting Defense Health Agency and military healthcare systems. The company's extensive federal contract portfolio demonstrates its capability to fulfill diverse pharmaceutical requirements on a competitive basis, encompassing brand-name and generic medications, vaccines, specialty drugs, and medical supplies across multiple therapeutic domains. This delivery order for Tagrisso reflects the company's ongoing role in supplying essential pharmaceutical commodities to support military medical readiness and healthcare operations.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $213.0k | 9/17/25 |